<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827151</url>
  </required_header>
  <id_info>
    <org_study_id>2008P00246</org_study_id>
    <secondary_id>NIH-HCNRC</secondary_id>
    <nct_id>NCT00827151</nct_id>
  </id_info>
  <brief_title>Bone Mass Accrual in Adolescent Athletes</brief_title>
  <acronym>838</acronym>
  <official_title>&quot;2008P-00346: Bone Mass Accrual in Adolescent Athletes&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The adolescent and young adult years are a critical window in time for bone mineral accrual.&#xD;
      More than 90% of peak bone mass is achieved by 18 years, and data indicate that insults&#xD;
      sustained during adolescence and young adulthood may result in permanent deficits in bone&#xD;
      accrual. Adult athletes with amenorrhea (AA) have low bone mineral density (BMD) secondary to&#xD;
      hypogonadism, associated with increased fracture risk and associated co-morbidities. We will&#xD;
      examine whether estrogen replacement will increase BMD and improve measures of bone&#xD;
      microarchitecture in adolescents and young women with AA, thus optimizing peak bone mass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Young female athletes 18-21 years old will be randomized to estrogen (and progesterone) with&#xD;
      lifestyle modification versus lifestyle modification alone for a 12 month period. Bone&#xD;
      density and structure will be assessed over this period. Hormonal evaluations will also be&#xD;
      performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was not funded&#xD;
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone density</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Amenorrhea</condition>
  <condition>Bone Loss</condition>
  <arm_group>
    <arm_group_label>Estrogen and lifestyle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen</intervention_name>
    <description>Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication</description>
    <arm_group_label>Estrogen and lifestyle</arm_group_label>
    <other_name>Vivelle-Dot</other_name>
    <other_name>Prometrium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  18-21 years of age&#xD;
&#xD;
          -  Hypothalamic amenorrhea&#xD;
&#xD;
          -  Greater than or equal to 15 years bone age&#xD;
&#xD;
          -  BMI between 10th-90th percentiles for age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medications affecting bone metabolism including estrogen/ progesterone,&#xD;
             anabolic steroids and glucocorticoids except local application of glucocorticoid&#xD;
             creams (washout period of three months necessary prior to study enrollment if&#xD;
             medically permissible to discontinue these)&#xD;
&#xD;
          -  Presence of anorexia nervosa or %IBW of &lt; 85% based on the 50th %ile of BMI for age&#xD;
&#xD;
          -  Spine BMD Z-score &lt; -3&#xD;
&#xD;
          -  Conditions other than endurance training that may cause amenorrhea including PCOS&#xD;
             (clinical or preceding laboratory evidence of hyperandrogenism with amenorrhea)&#xD;
&#xD;
          -  Conditions other than endurance training that may cause bone metabolism to be affected&#xD;
&#xD;
          -  Abnormal TSH, elevated FSH, hematocrit &lt; 30%&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        For girls with AA (to be randomized to estrogen and progesterone or no treatment)&#xD;
&#xD;
          -  History of migraines, hypertension, allergy to peanut oil, undiagnosed abnormal&#xD;
             genital bleeding, known, suspected or history of breast or genital cancer or estrogen&#xD;
             dependent neoplasia, known hypersensitivity to progesterone or estrogen or other&#xD;
             product ingredients, liver dysfunction or disease&#xD;
&#xD;
          -  LFTs greater than 1.5 times the upper limit of normal&#xD;
&#xD;
          -  Family history or personal history of conditions that may increase risk of&#xD;
             thromboembolism:&#xD;
&#xD;
               1. Family history of myocardial infarction or strokes occurring at less than 50&#xD;
                  years&#xD;
&#xD;
               2. Family history of clotting disorders: normal coagulation profile will be&#xD;
                  necessary for enrollment&#xD;
&#xD;
          -  History of smoking &gt;10 cigarettes a day (history of smoking &gt;14 cigarettes a day is a&#xD;
             contraindication for estrogen, but we will be more conservative in our exclusion&#xD;
             criteria)&#xD;
&#xD;
          -  Personal history of blood clots&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhu Misra, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 16, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Madhusmita Misra</investigator_full_name>
    <investigator_title>Professor Pediatrics</investigator_title>
  </responsible_party>
  <keyword>amenorrhea</keyword>
  <keyword>athletes</keyword>
  <keyword>bone loss</keyword>
  <keyword>eumenorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

